Key Highlights

  • GT Biopharma dosed the first patient in a Phase 1 trial of GTB-5550, its third TriKE immunotherapy to reach human testing and its first targeting solid tumors including prostate, ovarian, and lung cancer.
  • The company faces a November 16, 2026 Nasdaq deadline to regain minimum bid price compliance, with shares near $0.30 and a Series L preferred stock conversion price that has already reset dilutive anti-dilution protections to a $0.454 floor.
  • Cash of $8.9 million came almost entirely from financing rather than operations, with management guiding to a runway only through the fourth quarter of 2026 alongside a disclosed going-concern warning.

GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage cancer company built on one platform. TriKE, short for tri-specific killer engager, is a laboratory-built protein designed to grab a patient's natural killer (NK) cells, hold them against a tumour cell and switch them on.

Two May 2026 events now frame the stock. On 14 May the company dosed the first patient in a Phase 1 trial of GTB-5550, its third TriKE to reach human testing and its first in solid tumours. Six days later Nasdaq granted a second 180-day window to fix a sub-$1.00 share price.

The market has not rewarded the clinical progress. Shares closed near $0.30 on 13 August 2026 for a Market Value of roughly $13 million, according to MarketBeat. With second-quarter results outstanding and a listing deadline of 16 November 2026, the next three months carry unusual weight.

What Happened

GT Biopharma said on 14 May 2026 that the first patient had been dosed in a Phase 1 basket trial of GTB-5550, a TriKE targeting B7-H3, a protein on the surface of many solid tumours. The FDA cleared the investigational new drug (IND) application on 3 February 2026.

The study runs in two parts. Phase 1a escalates through up to six dose levels in prostate cancer to find the maximum tolerated dose. Phase 1b then expands into as many as seven tumour types: castration-resistant prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic and bladder cancer.

Delivery is a change. GTB-5550 is injected under the skin of the abdomen rather than infused, on five consecutive days in weeks one and two of a four-week cycle, with at least two cycles planned and 12-month survival follow-up.

Why It Matters

The lead programme, GTB-3650, targets CD33-expressing blood cancers, a small patient population. B7-H3 opens a far larger door. Announcing the IND submission in January 2026, chief executive Michael Breen said the trial targets a solid tumour population orders of magnitude larger than the myeloid blood cancer group.

The target choice rests on expression data the company cites showing B7-H3 in more than 90% of metastatic castration-resistant prostate cancer tumours, which is why prostate cancer anchors dose escalation and why PSA, the routine prostate blood marker, can give an early read on activity.

GTB-5550 is also the first dual-nanobody TriKE, linking a nanobody that engages CD16 on NK cells, a wildtype IL-15 segment that makes those cells multiply, and a nanobody that binds B7-H3. Nanobodies are miniaturised antibody fragments, which makes subcutaneous dosing practical.

The Numbers

GT Biopharma held $8.9 million in cash at 31 March 2026, up from $6.8 million at the end of 2025 and $2.6 million at 30 September 2025. That came from financing, not operations: $4.6 million arrived in the quarter, about $4.0 million from Series L preferred stock, against $2.5 million of operating burn.

The first-quarter net loss was $2.8 million, or $0.11 per share, versus $0.8 million a year earlier. R&D spending fell to $413,000 from $1.1 million, while general and administrative costs rose to $2.4 million from $833,000. The accumulated Deficit stands at $726.8 million.

Full-year 2025 produced a net loss of $28.4 million against $13.2 million in 2024, though the operating loss narrowed to $12.4 million from $14.4 million, with management pointing to a non-cash charge on Series L Investment rights.

GTB-3650 had treated eight patients across four cohorts as of the first-quarter update, cohort four complete at 10 micrograms per kilogram per day, in a design allowing up to seven cohorts and 14 patients.

What It Means for the Company

Running three clinical-stage programmes on under $10 million of cash is unusual, and it explains the spending pattern. R&D expense has fallen year on year even as the pipeline advanced, pointing to heavy reliance on academic collaborators rather than an expanding in-house operation.

Management guides to a cash runway through the fourth quarter of 2026, narrow for a company that has also disclosed substantial doubt about its ability to continue as a going concern. On 1 June 2026 it said artificial-intelligence tools had accelerated discovery, with new candidates anticipated to enter pre-IND development in 2027 -- a 2027 promise, not a 2026 catalyst.

Risks Investors Should Watch

Dilution is the most visible risk. Shares outstanding rose from about 25.5 million to 35.2 million in the first quarter alone and stood at 36.1 million on 8 May 2026; MarketBeat listed roughly 44.3 million in mid-August. Behind that sit 57.6 million warrants at a weighted average exercise price of $0.62 and a $20 million Equity Facility priced at 93% of volume-weighted average price.

The Series L preferred carries full-ratchet anti-dilution protection and its conversion price has already reset to a $0.454 floor, a mechanism that lifted the shares underlying the 2025 warrants from about 15 million to roughly 65 million.

Listing risk is dated. Nasdaq issued a minimum bid price notice on 20 November 2025 under Rule 5550(a)(2); the first 180-day period expired on 19 May 2026 and a second runs to 16 November 2026. Compliance needs a closing bid of $1.00 or above for 10 consecutive Business days, and the company flagged a possible reverse split.

Clinical risk is high. Both trials are Phase 1 dose-escalation studies with as few as two patients per cohort, and while GT Biopharma calls GTB-3650's safety profile excellent, it has published no efficacy data and no results at all for GTB-5550.

What Comes Next

Second-quarter results are the nearest event. As of 14 August 2026 no release had appeared on GT Biopharma's StockTitan news feed, and the most recent filing visible in EDGAR's submission record was the 22 May 2026 report on the Nasdaq extension.

The 2025 annual release said GTB-3650's cohort five, at 25 micrograms per kilogram per day, was planned for the second quarter of 2026 with the next update expected in the third. GTB-5550 updates are expected through the second half of 2026.

Conclusion

GT Biopharma is running three clinical-stage programs simultaneously on under $10 million of cash, a genuinely unusual feat that speaks to heavy reliance on academic collaborators rather than a fully resourced internal operation. The GTB-5550 dosing is a real milestone, opening a solid-tumor market far larger than the company's original blood cancer focus, but it comes with zero efficacy data yet and a Phase 1 dose-escalation design that won't produce meaningful signals for months. The more pressing near-term risk sits in the capital structure: full-ratchet anti-dilution provisions have already multiplied Warrant share counts, and the November Nasdaq deadline arrives before any clinical readout is expected.